Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
semaglutide
Pharma
JPM26: Novo CEO outlines R&D, marketing tactics for 2026
During a presentation, Maziar Doustdar—who was tapped to lead Novo Nordisk last summer—didn’t hesitate to acknowledge the company’s “difficult 2025.”
Fraiser Kansteiner
Jan 14, 2026 10:05am
Novo snags FDA nod for oral obesity med with Wegovy in a pill
Dec 22, 2025 6:59pm
Novo's oral semaglutide is PCPs' most-anticipated obesity med
Dec 15, 2025 3:46pm
Novo reports 2 trial failures for GLP-1 in Alzheimer's disease
Nov 24, 2025 11:41am
Semaglutide compounder drops claims after Novo Nordisk challenge
Nov 21, 2025 9:20am
Novo sets new self-pay prices for Wegovy, Ozempic
Nov 17, 2025 10:59am
